Top Markets
Coin of the day
MOLOGEN Lifescience AG MOLOGEN Lifescience AG

MOLOGEN Lifescience AG

U1DA
Rank in Stocks #40050
Finchain Capital Partners AG functions as an investment firm, concentrating its... Finchain Capital Partners AG functions as an investment firm, concentrating its capital deployment on early-stage companies, specifically during their seed, Series A, and Series B funding rounds. The company was established on February 27, 2015, and is based in Dusseldorf, Germany.
Share Price
$3.32
Last synced: 2026-08-13
Market Cap
$261.55K
Change (1 day)
0.00%
Change (1 year)
42.54%
Country
DE
Trade MOLOGEN Lifescience AG (U1DA)
P/E ratio for MOLOGEN Lifescience AG (U1DA)
P/E ratio as of 2026 TTM: 0
According to MOLOGEN Lifescience AG latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for MOLOGEN Lifescience AG from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
25.72 -
US
28.39 -
US
- -
SE
30.19 -
US
31.03 -
US
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.